ENDOV

Summary

ENDOV (endonuclease V, HGNC:26640) is a protein-coding gene on chromosome 17q25.3, encoding Endonuclease V (Q8N8Q3). Endoribonuclease that specifically cleaves inosine-containing RNAs: cleaves RNA at the second phosphodiester bond 3’ to inosine.

Enables DNA binding activity; RNA endonuclease activity, producing 5’-phosphomonoesters; and single-stranded RNA binding activity. Predicted to be involved in DNA repair. Located in cytoplasmic stress granule and nucleolus.

Source: NCBI Gene 284131 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 80 total
• MANE Select transcript: NM_173627

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:26640
Approved symbol	ENDOV
Name	endonuclease V
Location	17q25.3
Locus type	gene with protein product
Status	Approved
Aliases	FLJ35220
Ensembl gene	ENSG00000173818
Ensembl biotype	protein_coding
OMIM	619821
Entrez	284131

Gene structure

Transcript identifiers

Ensembl transcripts: 35 — 24 protein_coding, 5 protein_coding_CDS_not_defined, 3 nonsense_mediated_decay, 3 retained_intron

ENST00000323854, ENST00000517295, ENST00000517795, ENST00000518137, ENST00000518644, ENST00000518901, ENST00000518907, ENST00000519117, ENST00000519331, ENST00000520118, ENST00000520136, ENST00000520284, ENST00000520367, ENST00000520484, ENST00000520537, ENST00000520565, ENST00000520910, ENST00000521330, ENST00000521565, ENST00000521634, ENST00000521830, ENST00000521847, ENST00000522200, ENST00000522577, ENST00000522751, ENST00000523165, ENST00000523228, ENST00000523828, ENST00000523999, ENST00000572886, ENST00000858819, ENST00000858820, ENST00000858821, ENST00000858822, ENST00000858823

RefSeq mRNA: 5 — MANE Select: NM_173627 NM_001164637, NM_001164638, NM_001352760, NM_001352761, NM_173627

CCDS: CCDS54172, CCDS54173, CCDS54174

Canonical transcript exons

ENST00000518137 — 10 exons

Exon	Start	End
ENSE00002112997	80415167	80415250
ENSE00002498626	80429773	80429831
ENSE00003463496	80425032	80425100
ENSE00003480396	80423520	80423632
ENSE00003481097	80422206	80422245
ENSE00003495191	80415650	80415821
ENSE00003583431	80436133	80438086
ENSE00003595020	80421828	80421962
ENSE00003631980	80428596	80428660
ENSE00003789646	80425492	80425620

Expression profiles

Bgee: expression breadth ubiquitous, 219 present calls, max score 96.22.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 6.4211 / max 71.7681, expressed in 1747 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
163245	3.6552	1640
163246	2.7146	1361
163247	0.0513	10

Top tissues by expression

241 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
kidney epithelium	UBERON:0004819	96.22	gold quality
upper arm skin	UBERON:0004263	95.32	gold quality
parotid gland	UBERON:0001831	93.84	silver quality
right uterine tube	UBERON:0001302	92.32	gold quality
cardiac muscle of right atrium	UBERON:0003379	92.10	gold quality
left ventricle myocardium	UBERON:0006566	91.79	gold quality
lateral globus pallidus	UBERON:0002476	91.68	silver quality
vena cava	UBERON:0004087	91.18	silver quality
right hemisphere of cerebellum	UBERON:0014890	90.75	gold quality
cerebellar hemisphere	UBERON:0002245	90.49	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	90.37	gold quality
cerebellar cortex	UBERON:0002129	90.31	gold quality
cortical plate	UBERON:0005343	90.05	gold quality
left testis	UBERON:0004533	89.98	gold quality
metanephros cortex	UBERON:0010533	89.81	gold quality
cerebellum	UBERON:0002037	89.68	gold quality
right testis	UBERON:0004534	89.67	gold quality
adenohypophysis	UBERON:0002196	89.38	gold quality
epithelial cell of pancreas	CL:0000083	89.16	gold quality
nucleus accumbens	UBERON:0001882	89.06	gold quality
body of uterus	UBERON:0009853	89.04	gold quality
pituitary gland	UBERON:0000007	89.03	gold quality
substantia nigra pars reticulata	UBERON:0001966	89.00	silver quality
cardia of stomach	UBERON:0001162	88.98	silver quality
endocervix	UBERON:0000458	88.54	gold quality
substantia nigra pars compacta	UBERON:0001965	88.40	silver quality
left ovary	UBERON:0002119	88.39	gold quality
left lobe of thyroid gland	UBERON:0001120	88.36	gold quality
skin of leg	UBERON:0001511	88.26	gold quality
cortex of kidney	UBERON:0001225	88.21	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	3.83
E-GEOD-100618	no	91.84

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

54 targeting ENDOV, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-4668-3P	100.00	68.74	2635
HSA-MIR-3692-3P	99.98	70.27	2139
HSA-MIR-1229-3P	99.97	66.49	906
HSA-MIR-1236-3P	99.94	68.04	1695
HSA-MIR-7-1-3P	99.91	71.53	4384
HSA-MIR-7-2-3P	99.91	71.40	4394
HSA-MIR-1297	99.91	73.41	3162
HSA-MIR-548E-5P	99.89	72.73	4486
HSA-MIR-6817-3P	99.79	68.35	2126
HSA-MIR-4694-3P	99.79	69.53	2640
HSA-MIR-26A-5P	99.78	73.52	2303
HSA-MIR-26B-5P	99.78	73.51	2305
HSA-MIR-6763-5P	99.76	64.68	1767
HSA-MIR-7856-5P	99.75	69.99	2901
HSA-MIR-3913-3P	99.74	66.53	938
HSA-MIR-4306	99.72	70.50	3630
HSA-MIR-5580-3P	99.70	69.41	2052
HSA-MIR-7-5P	99.67	70.53	1809
HSA-MIR-3975	99.62	65.97	697
HSA-MIR-7152-5P	99.60	69.33	2094
HSA-MIR-12122	99.56	69.33	1672
HSA-MIR-451B	99.55	68.28	1380
HSA-MIR-186-3P	99.51	66.24	1685
HSA-MIR-5683	99.36	68.59	2083
HSA-MIR-10522-5P	99.26	68.50	2087
HSA-MIR-149-5P	99.25	67.16	1315
HSA-MIR-4477B	99.23	70.49	1733
HSA-MIR-122B-3P	99.21	68.90	1333
HSA-MIR-21-3P	99.21	68.95	1312

Literature-anchored findings (GeneRIF, showing 8)

• ENDOV is localized in the cytoplasm and nucleoli of human cells. (PMID:23139746)
• This previously unknown RNA incision activity may suggest a role for endonuclease V in normal RNA metabolism. (PMID:23912683)
• hEndoV controls the fate of inosine-containing RNA in humans. (PMID:23912718)
• ENDOV was significantly associated with schizophrenia. (PMID:25053281)
• Human EndoV appears inactive on DNA, but has been shown to incise various RNA substrates containing inosine. [review] (PMID:25824682)
• hEndoV is redistributed to stress granules as a strategy to create a local environment low in ATP to permit hEndoV activity. (PMID:27573237)
• Inosine-specific ribonuclease activity of natural variants of human endonuclease V (PMID:27800608)
• Base preference for inosine 3’-riboendonuclease activity of human endonuclease V: implications for cleavage of poly-A tails containing inosine. (PMID:38951658)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Endov	ENSMUSG00000039850
rattus_norvegicus	Endov	ENSRNOG00000003699

Protein

Protein identifiers

Endonuclease V — Q8N8Q3 (reviewed: Q8N8Q3)

Alternative names: Inosine-specific endoribonuclease

All UniProt accessions (15): Q8N8Q3, A0A0G2JLD4, E5RFW0, E5RGZ9, E5RHX4, E5RII5, E5RJ92, H0YAY5, H0YBX8, H0YBZ5, I3L0L4, I3L1V3, I3L485, I3L4M6, I3L4V7

UniProt curated annotations — full annotation on UniProt →

Function. Endoribonuclease that specifically cleaves inosine-containing RNAs: cleaves RNA at the second phosphodiester bond 3’ to inosine. Active against both single-stranded and double-stranded RNAs. Has strong preference for single-stranded RNAs (ssRNAs) toward double-stranded RNAs (dsRNAs). Cleaves mRNAs and tRNAs containing inosine. Also able to cleave structure-specific dsRNA substrates containing the specific sites 5’-IIUI-3’ and 5’-UIUU-3’. Inosine is present in a number of RNAs following editing; the function of inosine-specific endoribonuclease is still unclear: it could either play a regulatory role in edited RNAs, or be involved in antiviral response by removing the hyperedited long viral dsRNA genome that has undergone A-to-I editing. Binds branched DNA structures. Endoribonuclease that specifically cleaves inosine-containing RNAs: cleaves RNA at the second phosphodiester bond 3’ to inosine. Active against both single-stranded and double-stranded RNAs. Cleaves tRNAs containing inosine. Endoribonuclease that specifically cleaves inosine-containing RNAs: cleaves RNA at the second phosphodiester bond 3’ to inosine. Active against both single-stranded and double-stranded RNAs. Cleaves tRNAs containing inosine.

Subunit / interactions. Monomer. Interacts with PABPC1; the interaction is RNA-dependent and stimulates ENDOV activity.

Subcellular location. Cytoplasm. Nucleus. Nucleolus. Stress granule Cytoplasm. Stress granule.

Activity regulation. Inhibited by normal intracellular concentrations of ATP.

Similarity. Belongs to the endonuclease V family.

Isoforms (7)

UniProt ID	Names	Canonical?
Q8N8Q3-1	1, hENDOV 282	yes
Q8N8Q3-2	2
Q8N8Q3-3	3
Q8N8Q3-4	4
Q8N8Q3-5	5
Q8N8Q3-6	6, hENDOV 308
Q8N8Q3-7	7, hENDOV 309

RefSeq proteins (5): NP_001158109, NP_001158110, NP_001339689, NP_001339690, NP_775898* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR007581	Endonuclease-V	Family

Pfam: PF04493

Enzyme classification (BRENDA):

• EC 3.1.21.7 — deoxyribonuclease V (BRENDA: 17 organisms, 91 substrates, 22 inhibitors, 4 Km, 8 kcat entries)
• EC 3.1.27.8 — Ribonuclease V (BRENDA: 2 organisms, 7 substrates, 0 inhibitors, 1 Km, 0 kcat entries)

Substrate kinetics (BRENDA)

5 substrates with measured Km, best-characterized 5. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
49-MER OLIGONUCLEOTIDE	0.003–0.024	4
POLY(A)	0.0357	1
18-MER RNA OLIGONUCLEOTIDE CONTAINING INOSINE	—	0
30-MER DNA/RNA CONTAINING INOSINE HYBRID	—	0
ACUGGACA[RI][RI]U[RI]CUCCGAGG	—	0

UniProt features (50 total): mutagenesis site 15, strand 10, helix 8, sequence variant 5, splice variant 5, binding site 2, chain 1, region of interest 1, sequence conflict 1, turn 1, site 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
6OZE	X-RAY DIFFRACTION	1.5
4NSP	X-RAY DIFFRACTION	2.3

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8N8Q3-F1	90.90	0.83

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 91 (interaction with target rna)

Ligand- & substrate-binding residues (2): 52; 126

Mutagenesis-validated functional residues (15):

Position	Phenotype
35–40	does not gain activity against single- or double-stranded dna.
52	abolishes ribonuclease activity.
57–60	does not gain activity against single- or double-stranded dna.
90–93	abolishes ability to bind branched dna and rna.
91	abolishes ribonuclease activity without affecting ability to bind branched dna.
100	abolishes ribonuclease activity.
115–119	does not gain activity against single- or double-stranded dna.
161–166	does not gain activity against single- or double-stranded dna.
171	no effect on subcellular location or activity; when associated with a-174.
174	no effect on subcellular location or activity; when associated with a-171.
225	no significant effect on activity.
226	no significant effect on activity.
227	68% decrease in activity.
228	46% decrease in activity.
248–249	abolishes ability to bind branched dna and rna.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 94 (showing top): GOMF_ENDONUCLEASE_ACTIVITY, GOMF_RNA_NUCLEASE_ACTIVITY, GOMF_NUCLEASE_ACTIVITY, KAUFFMANN_DNA_REPAIR_GENES, GOMF_RNA_ENDONUCLEASE_ACTIVITY, GOBP_DNA_DAMAGE_RESPONSE, GOMF_DNA_ENDONUCLEASE_ACTIVITY, GOCC_CYTOPLASMIC_STRESS_GRANULE, GOCC_RIBONUCLEOPROTEIN_GRANULE, GOCC_NUCLEOLUS, GOBP_DNA_METABOLIC_PROCESS, SCGGAAGY_ELK1_02, GOMF_DNA_ENDONUCLEASE_ACTIVITY_PRODUCING_5_PHOSPHOMONOESTERS, MGGAAGTG_GABP_B, GOMF_MAGNESIUM_ION_BINDING

GO Biological Process (1): DNA repair (GO:0006281)

GO Molecular Function (12): magnesium ion binding (GO:0000287), DNA binding (GO:0003677), single-stranded RNA binding (GO:0003727), DNA endonuclease activity, producing 5’-phosphomonoesters (GO:0016888), RNA endonuclease activity producing 5’-phosphomonoesters, hydrolytic mechanism (GO:0016891), RNA binding (GO:0003723), nuclease activity (GO:0004518), endonuclease activity (GO:0004519), protein binding (GO:0005515), hydrolase activity (GO:0016787), hydrolase activity, acting on ester bonds (GO:0016788), metal ion binding (GO:0046872)

GO Cellular Component (4): nucleolus (GO:0005730), cytoplasm (GO:0005737), cytoplasmic stress granule (GO:0010494), nucleus (GO:0005634)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
nucleic acid binding	2
hydrolase activity, acting on ester bonds	2
DNA metabolic process	1
DNA damage response	1
metal ion binding	1
RNA binding	1
DNA endonuclease activity	1
RNA endonuclease activity	1
catalytic activity, acting on a nucleic acid	1
nuclease activity	1
binding	1
catalytic activity	1
hydrolase activity	1
cation binding	1
nuclear lumen	1
intracellular membraneless organelle	1
intracellular anatomical structure	1
cellular anatomical structure	1
cytoplasmic ribonucleoprotein granule	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

1632 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ENDOV	ITPA	Q9BY32	613
ENDOV	MPG	P29372	600
ENDOV	HENMT1	Q5T8I9	547
ENDOV	AGO3	Q9H9G7	545
ENDOV	AGO4	Q9HCK5	545
ENDOV	OGG1	P78554	507
ENDOV	UNG	P13051	505
ENDOV	TARBP2	Q15633	505
ENDOV	SND1	Q7KZF4	505
ENDOV	GEMIN5	Q8TEQ6	497
ENDOV	GEMIN6	Q8WXD5	496
ENDOV	ZFP36	P26651	490
ENDOV	PABPC1	P11940	484
ENDOV	PIWIL4	Q7Z3Z4	480
ENDOV	GEMIN2	O14893	470

IntAct

9 interactions, top by confidence:

A	B	Type	Score
IMPDH1	BCAT2	psi-mi:“MI:0914”(association)	0.530
ZNRD2	CCDC85C	psi-mi:“MI:0914”(association)	0.530
ENDOV	VWA8	psi-mi:“MI:0914”(association)	0.350
ZNRD2	KRBA1	psi-mi:“MI:0914”(association)	0.350
IMPDH1	MGST3	psi-mi:“MI:0914”(association)	0.350
ENDOV	PDCL	psi-mi:“MI:0914”(association)	0.350
ENDOV	PRPSAP2	psi-mi:“MI:0915”(physical association)	0.000
NELFCD	ENDOV	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (43): BBS2 (Affinity Capture-MS), VWA8 (Affinity Capture-MS), CCT2 (Affinity Capture-MS), ANKRD40 (Affinity Capture-MS), PDCL (Affinity Capture-MS), SEPHS2 (Affinity Capture-MS), RNF31 (Affinity Capture-MS), TSC22D3 (Affinity Capture-MS), APAF1 (Affinity Capture-MS), ENDOV (Affinity Capture-MS), SEPHS2 (Affinity Capture-MS), APAF1 (Affinity Capture-MS), RNF31 (Affinity Capture-MS), VWA8 (Affinity Capture-MS), TSC22D3 (Affinity Capture-MS)

ESM2 similar proteins: A0JNU3, A1A4L8, A2BDX3, A5GFZ6, A6NK58, A6QQ74, O19179, O43542, O60294, O95336, O95396, P19971, P85971, Q02846, Q05922, Q08DH8, Q0VFH3, Q28F19, Q29R99, Q2TBQ8, Q2V057, Q3SZ07, Q3UQ84, Q561R2, Q5ZKI2, Q68FW7, Q6PAT0, Q6QHF9, Q86U10, Q86WU2, Q86Y79, Q8BW00, Q8IVS8, Q8N8Q3, Q8R123, Q8VCZ9, Q8VDG5, Q8WV74, Q8WVB3, Q8WZ82

Diamond homologs: A0B8N3, A1AIG9, A1JIJ2, A1RY04, A4W5C1, A5FRP8, A5GD74, A5IL77, A5UWX7, A6LNA6, A6TGQ5, A7FNH1, A7MJ90, A7NSC5, A7ZUL4, A8A798, A8AKS5, A8G8F8, A9BHL9, A9MHD1, A9N0L0, B0RQR6, B1IUP9, B1LAF7, B1LNV0, B1XC01, B2IWL4, B2SRM7, B2TWI5, B2VG82, B4EYT7, B4T100, B4TCT7, B4TQK8, B5BJR7, B5F1I1, B5FQL3, B5QYF3, B5RFI6, B5XYE0

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

80 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	62
Likely benign	1
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

2644 predictions. Top by Δscore:

Variant	Effect	Δscore
17:80423630:AAG:A	donor_loss	1.0000
17:80423631:AGGTG:A	donor_loss	1.0000
17:80423633:G:C	donor_loss	1.0000
17:80423634:T:G	donor_loss	1.0000
17:80425101:G:A	donor_loss	1.0000
17:80425102:T:A	donor_loss	1.0000
17:80425619:AG:A	donor_loss	1.0000
17:80425620:GG:G	donor_loss	1.0000
17:80415393:G:GT	donor_gain	0.9900
17:80415399:G:GT	donor_gain	0.9900
17:80415411:G:GT	donor_gain	0.9900
17:80415412:A:T	donor_gain	0.9900
17:80415797:G:GA	donor_gain	0.9900
17:80417728:T:A	acceptor_gain	0.9900
17:80423514:T:TA	acceptor_gain	0.9900
17:80423516:GCA:G	acceptor_loss	0.9900
17:80423517:CAGG:C	acceptor_loss	0.9900
17:80423518:A:AG	acceptor_gain	0.9900
17:80423518:A:AT	acceptor_loss	0.9900
17:80423518:AG:A	acceptor_gain	0.9900
17:80423519:G:GA	acceptor_gain	0.9900
17:80423519:GG:G	acceptor_gain	0.9900
17:80423519:GGCT:G	acceptor_gain	0.9900
17:80423629:GAAG:G	donor_gain	0.9900
17:80425023:A:AG	acceptor_gain	0.9900
17:80425024:T:G	acceptor_gain	0.9900
17:80425027:TCCA:T	acceptor_loss	0.9900
17:80425028:CCAG:C	acceptor_loss	0.9900
17:80425029:CAGAT:C	acceptor_loss	0.9900
17:80425030:A:AG	acceptor_gain	0.9900

AlphaMissense

1788 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:80422219:A:T	D126V	0.995
17:80422228:G:A	G129E	0.995
17:80423581:G:C	K155N	0.995
17:80423581:G:T	K155N	0.995
17:80422227:G:T	G129W	0.993
17:80415699:T:A	W36R	0.992
17:80415699:T:C	W36R	0.992
17:80415756:T:C	F55L	0.992
17:80415758:C:A	F55L	0.992
17:80415758:C:G	F55L	0.992
17:80421891:T:C	F98L	0.992
17:80421893:C:A	F98L	0.992
17:80421893:C:G	F98L	0.992
17:80415749:C:A	D52E	0.991
17:80415749:C:G	D52E	0.991
17:80421958:C:A	P120H	0.991
17:80422220:T:A	D126E	0.990
17:80422220:T:G	D126E	0.990
17:80422222:G:A	G127E	0.990
17:80422228:G:T	G129V	0.990
17:80423526:G:A	G137E	0.990
17:80423535:G:A	C140Y	0.990
17:80423544:G:A	G143D	0.990
17:80425615:C:A	R237S	0.990
17:80415739:G:A	G49E	0.989
17:80421882:T:C	F95L	0.989
17:80421884:C:A	F95L	0.989
17:80421884:C:G	F95L	0.989
17:80422236:C:G	H132D	0.989
17:80423536:C:G	C140W	0.989

dbSNP variants (sampled 300 via entrez): RS1000082669 (17:80423936 G>A), RS1000246146 (17:80428012 C>T), RS1000378664 (17:80437498 G>A), RS1000473972 (17:80427591 A>T), RS1000536666 (17:80433648 C>T), RS1000545895 (17:80427377 C>T), RS1000559233 (17:80423749 C>G,T), RS1000590643 (17:80434137 C>A,T), RS1000665565 (17:80432837 C>T), RS1000711916 (17:80438491 C>T), RS1000834115 (17:80424946 C>G,T), RS1000839423 (17:80415355 C>A,G,T), RS1000969571 (17:80433876 G>C), RS1000976654 (17:80420796 G>C), RS1000980010 (17:80418897 C>T)

Disease associations

OMIM: gene MIM:619821 | disease phenotypes: MIM:607151

GenCC curated gene-disease

Mondo (1): Moyamoya disease 2 (MONDO:0011784)

Orphanet (1): Moyamoya disease (Orphanet:2573)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST009204_12	Total intracranial volume	9.000000e-06

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004886	intracranial volume measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
C536992	Moyamoya disease 2 (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

20 total (human), top 20 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
aristolochic acid I	increases expression	1
FR900359	increases phosphorylation	1
triphenyl phosphate	affects expression	1
sodium arsenite	increases expression	1
benzo(e)pyrene	decreases methylation	1
ferrous chloride	decreases expression	1
abrine	increases expression	1
Grape Seed Proanthocyanidins	decreases expression, affects cotreatment	1
Acetaminophen	decreases expression	1
Benzo(a)pyrene	affects methylation	1
Catechin	decreases expression, affects cotreatment	1
Dichlorodiphenyl Dichloroethylene	decreases expression	1
Methapyrilene	decreases methylation	1
Phthalic Acids	increases methylation	1
Silicon Dioxide	decreases expression	1
Smoke	decreases expression	1
Valproic Acid	increases methylation	1
Aflatoxin B1	decreases methylation	1
Antirheumatic Agents	increases expression	1
Particulate Matter	increases expression	1

Cellosaurus cell lines

2 cell lines: 1 transformed cell line, 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D9E9	Ubigene HEK293 ENDOV KO	Transformed cell line	Female
CVCL_SM05	HAP1 ENDOV (-)	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.